Archives: Contractor Email

Dear Colleague,

REMINDER: COMMUNITY PHARMACY ADVICE ON FACE COVERINGS

Please find below CPNI Contractor email sent on 19th August 2020 and also attached letter from the Chief Pharmaceutical Officer sent on 10th September 2020 regarding face coverings.

Yours sincerely

SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive

CPNI COVID19 CU#123 RE: Face Coverings Poster

Download

Dear Colleague,

The following concessionary prices have been granted for October 2020:

Drug Pack Size Concessionary Price
Duloxetine 20mg gastro-resistant capsules 28 £7.99
Duloxetine 60mg gastro-resistant capsules 28 £4.10
Enalapril 10mg tablets 28 £5.49
Enalapril 20mg tablets 28 £10.00
Estradiol 1mg tablets 84 £6.89
Estradiol 2mg tablets 84 £6.89
Hydroxyzine 10mg tablets 84 £1.77
Moxonidine 200microgram tablets 28 £9.46
Moxonidine 300microgram tablets 28 £10.99
Moxonidine 400microgram tablets 28 £12.07
Naftidrofuryl 100mg capsules 84 £7.25
Olanzapine 15mg tablets 28 £3.95
Olanzapine 20mg tablets 28 £5.10
Oxytetracycline 250mg tablets 28 £9.10
Senna 7.5mg tablets 60 £2.76
Sertraline 100mg tablets 28 £6.72
Sertraline 50mg tablets 28 £4.74
Valsartan 160mg capsules 28 £12.01

This is the first update of concessionary prices for October 2020.

Concessionary prices will be paid against the usual code, no additional endorsements are needed.

Concessionary prices may be granted up until the end of the month so CPNI will notify you of any further concessionary prices as and when they are agreed.

Please continue to notify CPNI of any pricing issues you are experiencing.

Concessionary prices are also published on the CPNI website www.communitypharmacyni.co.uk

Kind regards,

Katherine

SENT FOR AND BEHALF OF KATHERINE KIDD | Head of Pharmacy Development

Dear Colleague

ADHERENCE SUPPORT: COMMUNITY PHARMACY REVIEW OF PATIENTS RECEIVING MONITORED DOSAGE SYSTEMS (MDS)

Please find attached for your attention, correspondence from Joe Brogan, Assistant Director of Integrated Care, Head of Pharmacy and Medicines Management.

Given the challenges faced within the wider system, there is a need to urgently address the current and ongoing need for pharmacy adherence support particularly in order to plan for a potential second surge of COVID-19. The letter outlines the process for a community pharmacy-led review and the associated remuneration.

The purpose of the community pharmacy-led review is to identify patients for whom MDS must continue as it is deemed vital in order for them to manage their medicines safely. This review process should help to identify patients where use of MDS may not be necessary or where other options may be safely considered

A review of all eligible patients should be completed and the summary template and claim form returned to your local HSCB office by Friday 16th October 2020.

Please bring the attached letter and associated documentation to the attention of your pharmacist(s) involved in review of MDS patients.

If you have any queries in relation to this correspondence, please contact your local HSCB Pharmacy Adviser in the first instance or the CPNI office.

Yours sincerely

SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive

Download

Dear Colleague,

Please find attached a ‘Save the Date’ Document ahead of the next Echo session, scheduled to take place on 27th October 2020 from 7.30pm to 9.00pm.

Also attached is ‘Project ECHO – Enhanced Security Measures’ which should be reviewed, ahead of the next Echo Session.

An agenda will be issued shortly.

Please share this with your pharmacist(s).

Yours sincerely

SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive

Download

Dear Contractor

Update to Serious Shortage Protocols: Fluoxetine 40mg Capsules

The Department of Health NI has issued correspondence (attached) regarding the current Serious Shortage Protocol (SSP) for fluoxetine 40mg capsules.

The Department advises that fluoxetine 40mg capsules are now back in stock at local wholesalers and, therefore, the SSP that is currently in force will end on Friday 16 October 2020 and will not be renewed.

Action

Contractors are advised to: Bring the content of the letter to the attention of their dispensing teams.

Further information on SSPs is available on the BSO website which can be accessed via this link:

www.hscbusiness.hscni.net/services/3063.htm

CPNI colleagues will continue to support contractors on these matters.

Kind regards

Mike

Sent on behalf of Prof Mike Mawhinney | Head of Regulatory Affairs

Download

Dear Colleague,

CPNI COVID Update #133 (1st Oct), outlined the updated process for reordering of PPE and CPNI Contractor Update 201002B (2nd Oct), outlined the PPE requirements for the flu vaccination service.

For CPNI contractor emails click: here

PPE for Pharmacy Staff

  • Pharmacy teams are reminded that a fluid resistant surgical mask is the recommended PPE when working in an area with possible or confirmed case(s) and unable to maintain 2 metres social distance.
  • Face visors or Eye/face protection may be worn, but this should be in addition to the face mask where it has been risk assessed e.g. Flu vaccination clinic or when supervising OST consumption.
  • For more information click on the following links:

Community Pharmacy Flu Vaccination Service

Face Visors

  • NI direct website advises the general public: face visors do not offer the same protection as a face covering which covers the nose and the mouth.
  • The use of cloth face coverings are therefore recommended, as they provide much better protection from the risk of infection from the COVID-19 virus.

Please share this information with your pharmacy team(s).  For any PPE queries please contact your local HSCB office or alternatively the CPNI office.

For all COVID related queries and advice, please phone the PHA duty room 0300 555 0119.

Yours sincerely

SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive